{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002002","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.414665+00:00","generated_at":"2026-05-25T20:45:26.517623+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved","bullets":["Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.","Net loss $80.5M for FY2024 vs $69.3M in FY2023; R&D expense $79.0M.","Global pivotal Phase 3 FURVENT study for firmonertinib in EGFR exon20ins NSCLC reached target enrollment of 375 patients.","Selected next-generation ADC candidate ARR-002 for IND-enabling studies; in-licensed ARR-217 (MRG007) from Lepu Biopharma.","Plan to provide update on firmonertinib in EGFR PACC mutant NSCLC in H1 2025; top-line Phase 3 data expected in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002002","json":"https://secwatch.observer/filing/0001558370-25-002002.json","markdown":"https://secwatch.observer/filing/0001558370-25-002002.md","text":"https://secwatch.observer/filing/0001558370-25-002002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/0001558370-25-002002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T20:45:26.517623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}